[
    [
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
            "features": {
                "keywords": [
                    "年报",
                    "季报",
                    "医药",
                    "野蛮扩张",
                    "结构优化",
                    "医药流通"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智飞生物股东吴冠江减持3452万股 套现约17.56亿元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "股东",
                    "吴冠江",
                    "减持",
                    "套现"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物股东吴冠江减持3452万股 套现约17.56亿元",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "海南“假疫苗”案：利润率高达80%，8000元罚款能否警世？ 其他违规处罚",
            "features": {
                "keywords": [
                    "假疫苗",
                    "海南",
                    "利润率",
                    "罚款",
                    "违规处罚"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "海南“假疫苗”案：利润率高达80%，8000元罚款能否警世？ 其他违规处罚",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]